111
Participants
Start Date
November 30, 2020
Primary Completion Date
July 20, 2021
Study Completion Date
July 20, 2021
Rivaroxaban
Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and \<50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
Standard Of Care (SOC)
Standard of care treatment
Department of Pneumology and Infectology Charité University Medicine Berlin, Campus Mitte, Berlin
Department of Cardiology Charité University Medicine Berlin, Campus Benjamin Franklin, Berlin
Internal Medicine/Cardiology department Unfallkrankenhaus Berlin, Berlin
Pulmonary Clinic Berlin-Buch (Lungenklinik Berlin-Buch), Berlin
Department of Cardiology Charité University Medicine Berlin, Campus Virchow, Berlin
Internal Medicine, Cardiology and Intensive Care Clinic Vivantes Humboldt Klinikum, Berlin, Berlin
Berlin Vivantes Hospital Spandau Clinic for internal medicine, cardiology and conservative intensive care medicine, Berlin
Internal Medicine Deparment Hospital Waldfriede, Berlin, Berlin
Immanuel Klinikum Bernau Herzzentrum Brandenburg ( Immanuel Clinic Bernau Heart Center Brandenburg), Bernau bei Berlin
Internal Medicine and Cardiology Klinik Henningsdorf. Oberhavel Kliniken, Hennigsdorf
Medical Clinic II, University Clinic Schleswig-Holstein - Campus Lübeck, Lübeck
Clinic for Cardiology and Intensive Care - Klinikum Bielefeld, Bielefeld
Pneumology, Allergology, Sleep-and Respiratory Medicine Clinic Helios Universitätsklinikum Wupperthal, Wuppertal
Medical Clinic I. Marien Hospital, Universitätsklinikum der Ruhr Universität Bochum, Herne, Herne
Westdeutsches Herz- und Gefäßzentrum Essen (West German Heart and Vascular Center Essen), Essen
Center for Cardiology, University Medicine Mainz, Mainz
Katholisches Klinikum Koblenz-Montabaur (Catholic Hospital Koblenz-Montabaur), Koblenz
Clinic for Cardiology, Angiology und Nephrology Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main
Clinic for Gastroenterology, Infectology and Poisoning Universitäsklinikum Heidelberg, Heidelberg
Kardiologie und Angiologie I Universitätsherzzentrum Freiburg, Freiburg im Breisgau
Medical Clinic and Polyclinic I. L. Ludwigs-Maximilians-University Clinic, Munich, Munich
Friedrichshafen Hospital Clinic for cardiology, angiology, pneumology and internal intensive care medicine, Friedrichshafen
Medical Clinic I. Universitätsklinikum Carl Gustav Carus, Dresden, Dresden
Universitätsklinikum Halle (Saale) (University Hospital Halle (Saale)), Halle
Collaborators (1)
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
OTHER
Bayer
INDUSTRY
Charite University, Berlin, Germany
OTHER